RATIONALE: Increases in depressive symptoms during smoking cessation have been associated with risk for relapse. Several studies have linked plasma levels of cortisol and dehydroepiandrosterone (DHEA) or DHEA-sulfate (DHEAS) to depressive symptoms. OBJECTIVES: To determine whether changes in plasma cortisol, DHEA, or DHEAS levels and emergence of depressive symptoms during smoking cessation are associated with smoking relapse. MATERIALS AND METHODS:Subjects were healthy non-medicated men and women, aged 39+/-12 years, who smoked, on average, 22 cigarettes per day. Depressive symptoms, smoking withdrawal symptoms, and plasma steroid levels were measured before and after 8 days of verified smoking abstinence. Relapse status at day 15 was then determined. RESULTS: In the full sample (n=63), there was a trend for changes in depressive symptoms to be associated with relapse. In the subset of 25 subjects with plasma neuroactive steroid data, there was a significant interaction between the change in the plasma DHEA/cortisol ratio from day 0 to day 8 and relapse status at day 15. This ratio was similar before abstinence, but lower at day 8 in relapsed, compared to abstinent, subjects. Changes in the DHEA/cortisol ratio tended to predict changes in depressive symptoms in the women only. CONCLUSION: A decrease in the plasma DHEA/cortisol ratio during 8 days of smoking abstinence was associated with relapse over the following week. Further research is needed to fully characterize sex-specific relationships between abstinence-induced changes in neuroactive steroid levels, depressive or withdrawal symptoms, and relapse. Such research may lead to new interventions for refractory smoking dependence.
RCT Entities:
RATIONALE: Increases in depressive symptoms during smoking cessation have been associated with risk for relapse. Several studies have linked plasma levels of cortisol and dehydroepiandrosterone (DHEA) or DHEA-sulfate (DHEAS) to depressive symptoms. OBJECTIVES: To determine whether changes in plasma cortisol, DHEA, or DHEAS levels and emergence of depressive symptoms during smoking cessation are associated with smoking relapse. MATERIALS AND METHODS: Subjects were healthy non-medicated men and women, aged 39+/-12 years, who smoked, on average, 22 cigarettes per day. Depressive symptoms, smoking withdrawal symptoms, and plasma steroid levels were measured before and after 8 days of verified smoking abstinence. Relapse status at day 15 was then determined. RESULTS: In the full sample (n=63), there was a trend for changes in depressive symptoms to be associated with relapse. In the subset of 25 subjects with plasma neuroactive steroid data, there was a significant interaction between the change in the plasma DHEA/cortisol ratio from day 0 to day 8 and relapse status at day 15. This ratio was similar before abstinence, but lower at day 8 in relapsed, compared to abstinent, subjects. Changes in the DHEA/cortisol ratio tended to predict changes in depressive symptoms in the women only. CONCLUSION: A decrease in the plasma DHEA/cortisol ratio during 8 days of smoking abstinence was associated with relapse over the following week. Further research is needed to fully characterize sex-specific relationships between abstinence-induced changes in neuroactive steroid levels, depressive or withdrawal symptoms, and relapse. Such research may lead to new interventions for refractory smoking dependence.
Authors: O M Wolkowitz; V I Reus; A Keebler; N Nelson; M Friedland; L Brizendine; E Roberts Journal: Am J Psychiatry Date: 1999-04 Impact factor: 18.112
Authors: Peter J Schmidt; Robert C Daly; Miki Bloch; Mark J Smith; Merry A Danaceau; Linda Simpson St Clair; Jean H Murphy; Nazli Haq; David R Rubinow Journal: Arch Gen Psychiatry Date: 2005-02
Authors: Rael D Strous; Rachel Maayan; Raya Lapidus; Rafael Stryjer; Michal Lustig; Moshe Kotler; Abraham Weizman Journal: Arch Gen Psychiatry Date: 2003-02
Authors: Anthony P King; Jennifer N Leichtman; James L Abelson; Israel Liberzon; Julia S Seng Journal: J Am Psychiatr Nurses Assoc Date: 2008-08 Impact factor: 2.385
Authors: Elizabeth E Van Voorhees; Michelle F Dennis; Patrick S Calhoun; Jean C Beckham Journal: Int Clin Psychopharmacol Date: 2014-01 Impact factor: 1.659
Authors: R O'Hara; C M Schröder; R Mahadevan; A F Schatzberg; S Lindley; S Fox; M Weiner; H C Kraemer; A Noda; X Lin; H L Gray; J F Hallmayer Journal: Mol Psychiatry Date: 2007-03-13 Impact factor: 15.992
Authors: Elizabeth E Van Voorhees; Michelle F Dennis; F Joseph McClernon; Patrick S Calhoun; Natalie A Buse; Jean C Beckham Journal: J Clin Psychopharmacol Date: 2013-08 Impact factor: 3.153